{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(4)"],"submitter":["Lefranc MP"],"pubmed_abstract":["The constant region of the immunoglobulin (IG) or antibody heavy gamma chain is frequently engineered to modify the effector properties of the therapeutic monoclonal antibodies. These variants are classified in regards to their effects on effector functions, antibody-dependent cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) enhancement or reduction, B cell inhibition by the coengagement of antigen and FcγR on the same cell, on half-life increase, and/or on structure such as prevention of IgG4 half-IG exchange, hexamerisation, knobs-into-holes and the heteropairing H-H of bispecific antibodies, absence of disulfide bridge inter H-L, absence of glycosylation site, and site-specific drug attachment engineered cysteine. The IMGT engineered v"],"journal":["Antibodies (Basel, Switzerland)"],"pagination":["65"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9624366"],"repository":["biostudies-literature"],"pubmed_title":["IMGT <sup>®</sup> Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats."],"pmcid":["PMC9624366"],"pubmed_authors":["Lefranc G","Lefranc MP"],"additional_accession":[]},"is_claimable":false,"name":"IMGT <sup>®</sup> Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats.","description":"The constant region of the immunoglobulin (IG) or antibody heavy gamma chain is frequently engineered to modify the effector properties of the therapeutic monoclonal antibodies. These variants are classified in regards to their effects on effector functions, antibody-dependent cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) enhancement or reduction, B cell inhibition by the coengagement of antigen and FcγR on the same cell, on half-life increase, and/or on structure such as prevention of IgG4 half-IG exchange, hexamerisation, knobs-into-holes and the heteropairing H-H of bispecific antibodies, absence of disulfide bridge inter H-L, absence of glycosylation site, and site-specific drug attachment engineered cysteine. The IMGT engineered v","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-08T03:13:45.113Z","creation":"2025-04-21T14:18:17.156Z"},"accession":"S-EPMC9624366","cross_references":{"pubmed":["36278618"],"doi":["10.3390/antib11040065"]}}